Heron Therapeuti (HRTX)vsEli Lilly and Company (LLY)
HRTX
Heron Therapeuti
$0.28
-8.44%
HEALTHCARE · Cap: $56.69M
LLY
Eli Lilly and Company
$1,433.55
-0.82%
HEALTHCARE · Cap: $1.27T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 57092% more annual revenue ($86.46B vs $151.18M). LLY leads profitability with a 31.9% profit margin vs -22.5%. LLY earns a higher WallStSmart Score of 74/100 (B).
HRTX
Avoid29
out of 100
Grade: F
LLY
Strong Buy74
out of 100
Grade: B
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 51.2%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Areas to Watch
Trading at 9.5x book value
1.3% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : HRTX
HRTX has a balanced fundamental profile.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 51.2%. Revenue growth of 38.6% demonstrates continued momentum.
Bear Case : HRTX
The primary concerns for HRTX are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 26.80 is elevated, increasing financial risk.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.3x leaves little room for execution misses.
Key Dynamics to Monitor
HRTX profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
HRTX carries more volatility with a beta of 1.65 — expect wider price swings.
LLY is growing revenue faster at 38.6% — sustainability is the question.
LLY generates stronger free cash flow (8.2B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (74/100 vs 29/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Heron Therapeuti
HEALTHCARE · BIOTECHNOLOGY · USA
Heron Therapeutics, Inc., a biotechnology company, is dedicated to developing treatments to address unmet medical needs. The company is headquartered in San Diego, California.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?